Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Acadia Pharmaceutica (ACAD)

Acadia Pharmaceutica (ACAD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Acadia Pharmaceutica 12830 El Camino Real Suite 400 SAN DIEGO CA 92130 USA

www.acadia.com Employees: 798 P: 858-558-2871 F: 858-212-0513

Sector:

Medical

Description:

Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on developing innovative medicines to address the unmet medical needs in central nervous system (CNS) disorders. The company's sole marketed drug Nuplazid (pimavanserin) is the first and the only FDA-approved treatment for hallucinations and delusions associated with Parkinson's disease psychosis. The company suffered a setback when the FDA issued a complete response letter to the supplemental new drug application for Nuplazid for treating dementia-related psychosis. Acadia resubmitted the supplemental new drug application to the FDA for pimavanserin for the treatment of hallucinations and delusions associated with Alzheimer's disease psychosis. Notably, several additional studies on Nuplazid n targeting different CNS indications, such as'dementia-related psychosis, schizophrenia inadequate response, schizophrenia negative symptoms and as an adjunctive treatment of major depressive disorder (MDD) are currently underway.

Key Statistics

Overview:

Market Capitalization, $K 3,578,690
Enterprise Value, $K 3,400,990
Shares Outstanding, K 170,495
Float, K 122,245
% Float 71.70%
Short Interest, K 9,490
Short Float 5.57%
Days to Cover 4.96
Short Volume Ratio 0.45
% of Insider Shareholders 28.30%
% of Institutional Shareholders 96.71%

Financials:

Annual Sales, $ 1,072 M
Annual Net Income, $ 391,000 K
Last Quarter Sales, $ 283,990 K
Last Quarter Net Income, $ 273,570 K
EBIT, $ 104,810 K
EBITDA, $ 111,150 K

Growth:

1-Year Return 21.65%
3-Year Return 11.37%
5-Year Return -18.09%
5-Year Revenue Growth 142.55%
5-Year Earnings Growth 146.93%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 0.16 on 02/25/26
Next Earnings Date 05/06/26
Earnings Per Share ttm 0.69
EPS Growth vs. Prev Qtr -38.46%
EPS Growth vs. Prev Year -5.88%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%

ACAD Ratios

Ratio
Price/Earnings ttm 30.06
Price/Earnings forward 44.13
Price/Earnings to Growth 20.62
Return-on-Equity % 12.49%
Return-on-Assets % 8.88%
Profit Margin % 36.49%
Debt/Equity 0.00
Price/Sales 3.30
Price/Cash Flow 23.38
Price/Book 2.86
Book Value/Share 7.25
Interest Coverage -1.25
60-Month Beta 0.66
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.